We have performed a review of literature to find evidence on the effectiveness of the different methods used to decrease pain perception during office hysteroscopy and identify risk factors of a painful hysteroscopy. Our methods include a review of literature following the Meta-analysis of Observational Studies in Epidemiology (MOOSE) Guidelines for Systematic Reviews of Observational Studies; a literature search of MEDLINE, Embase, PubMed, and the Cochrane Library of Systematic Reviews; and reference search in selected papers, looking for meta-analysis and randomized controlled trials that assess pain management in office hysteroscopy and studies that identify risk factors for painful hysteroscopy. Review for appropriateness and allocation according to type of analgesic method was performed, together with evaluation for risk factors and evidence of pain reduction effects of pharmacological and nonpharmacological analgesic methods. Nonpharmacological methods, such as vaginoscopy or minihysteroscopes, are advisable to avoid producing pain. The only pharmacological method that has demonstrated its effectiveness in several meta-analysis and reviews is paracervical block, reducing pain during and 30 minutes after hysteroscopy. Nonsteroidal anti-inflammatory drugs (NSAIDs) seem to be useful in the postoperative period. Evidence is not clear about combination of techniques or misoprostol. Although this review is limited because of heterogeneity of the studies included, it gives a wide overview of the different methods that are available to alleviate pain in office hysteroscopy. Paracervical infiltration is the only anesthetic procedure that has proven effective for pain reduction. Other methods such as using NSAIDs, topical anesthetics, misoprostol, or nitrous oxide have to be better studied to reach conclusions on their effectiveness

Background There is controversy surrounding the risk of ischemic stroke associated with the use of calcium supplements either in monotherapy or in combination with vitamin D. Methods and Results A nested case‐control study was performed with patients aged 40 to 89 years old, among whom a total of 2690 patients had a first episode of nonfatal ischemic stroke and for which 19 538 controls were randomly selected from the source population and frequency‐matched with cases for age, sex, and calendar year. Logistic regression provided the odds ratios while adjusting for confounding factors. A sensitivity analysis was performed by restricting to patients who were new users of calcium supplements as either monotherapy or with vitamin D. Calcium supplementation with vitamin D was not associated with an increased risk of ischemic stroke (odds ratio 0.85; 95% confidence interval, 0.67–1.08) in the population as a whole or under any of the conditions examined (dose, duration, background cardiovascular risk, sex, or age). Calcium supplement monotherapy was not associated with an increased risk in the population as a whole (odds ratio 1.18; 95% confidence interval, 0.86–1.61), although a significant increased risk at high doses (≥1000 mg/day: odds ratio 2.09; 95% confidence interval, 1.25–3.49; <1000 mg: odds ratio 0.76; 95% confidence interval, 0.45–1.26) compared with nonuse was observed. The sensitivity analysis did not affect the inferences, with similar results observed among new users as to the overall study population. Conclusions This study suggests that calcium supplements given as monotherapy at high doses may increase the risk of ischemic stroke, whereas their combination with vitamin D seems to offset this hazard.